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 Glycogenin-interacting protein 1 (GNIP1) is a tripartite motif (TRIM) protein with E3 
ubiquitin ligase activity that interacts with glycogenin. These data suggest that GNIP1 
could play a major role in the control of glycogen metabolism. However, direct 
evidence based on functional analysis remains to be obtained.  
Objectives 
The aim of this study was 1) to define the expression pattern of glycogenin-interacting 
protein/Tripartite motif containing protein 7 (GNIP/TRIM7) isoforms in humans, 2)  to 
test their ubiquitin E3 ligase activity, and 3) to analyze the functional effects of GNIP1 
on muscle glucose/glycogen metabolism both in human cultured cells and in vivo in 
mice.  
Results 
We show that GNIP1 was the most abundant GNIP/TRIM7 isoform in human skeletal 
muscle, whereas in cardiac muscle only TRIM7 was expressed. GNIP1 and TRIM7 had 
autoubiquitination activity in vitro and were localized in the Golgi apparatus and 
cytosol respectively in LHCN-M2 myoblasts. GNIP1 overexpression increased glucose 
uptake in LHCN-M2 myotubes. Overexpression of GNIP1 in mouse muscle in vivo 
increased glycogen content, glycogen synthase (GS) activity and phospho-GSK-3α/β 
(Ser21/9) and phospho-Akt (Ser473) content, whereas decreased GS phosphorylation in 
Ser640. These modifications led to decreased blood glucose levels, lactate levels and 
body weight,  without changing whole-body insulin or glucose tolerance in mouse.  
Conclusion 










































































GNIP1: TRIM7 isoform 1 





Akt: Protein kinase B 
CM: Cardiac muscle 
GP: Glycogen phosphorylase 
GS: Glycogen synthase 
GSK-3: Glycogen synthase kinase 3  
GST: Glutathione S-tranferase 
GYG1: Glycogenin 1 
SKM: Skeletal muscle 
 
1. INTRODUCTION 
Glycogen metabolism is crucial for skeletal muscle (SKM) activity in humans, since 
glycogen hydrolysis supplies glucose to the muscle cells during muscle contraction. 
Glycogen synthesis requires a series of reactions that include glycogenin 1 (GYG1) 
self-glucosylation, which forms an oligosaccharide primer that serves as substrate for 
glycogen synthase (GS) [1]. 
Recently, in the search for proteins that interact with GYG1, the cDNA for a protein 
designated glycogenin-interacting protein (GNIP) was isolated from the human SKM 






































































three transcripts that were designated GNIP1, GNIP2, and GNIP3 and another one 
identical to previously identified tripartite motif containing protein 7 (TRIM7). TRIM7 
cDNA was initially identified and cloned from mouse and human [3], and was found to 
be mainly expressed in SKM in adults. 
The tripartite motif (TRIM) protein family is defined by the presence of a tripartite 
motif composed of a RING domain, one or two B-box motifs and a coiled-coil region 
[4]. The structure-function analysis of GNIP/TRIM7 proteins revealed that GNIP1, 
GNIP2, and GNIP3 have in common (from the N- to C-terminus), a predicted coiled-
coil region and a B30.2-like domain. GNIP2 and GNIP3 are truncated so that a shorter 
fragment of the coiled-coil domain is N-terminal. GNIP1 has a predicted N-terminal 
RING finger domain and a B box domain. The N-terminal 206 amino acids of TRIM7 
are identical to those of GNIP1, including the predicted RING and a B box domain, and 
the C-terminus of TRIM7 bears a coiled-coil domain that is short and unique [5].  Thus, 
GNIP1 and TRIM7 have in common the N-terminal end, and are members of the TRIM 
protein family. TRIM proteins have been implicated in a broad range of biological 
processes and metabolic disorders, including obesity and insulin resistance in mouse [6] 
and human [7].  The activity of most E3 ligases is specified by a RING domain, which 
plays a critical role in ubiquitination [8]. Ubiquitination is a post-translational 
modification mechanism that controls protein levels through proteasome-mediated 
proteolysis and may also regulate protein activity and subcellular localization [9, 10]. 
Protein ubiquitination requires the participation of E1 ubiquitin-activating enzymes, E2 
ubiquitin-conjugating enzymes, and E3 ubiquitin ligases. GNIP1 was recently 
characterized as an ubiquitin ligase [11], but the potential ubiquitin E3 ligase activity of 
TRIM7 (predicted by the RING domain) has not been demonstrated. Moreover, it has 
been found by yeast two-hybrid assay that GNIP2, which is not a member of the TRIM 
protein family, and GNIP1 interact with GYG1. Furthermore, GNIP2 was shown to 
stimulate GYG1 self-glucosylation in vitro [2], and the B30.2 domain was reported to 
mediate GNIP2 interaction with GYG1 [5]. All these data suggest that GNIP1 is an 
ubiquitin ligase that plays a role in glycogen metabolism in muscle, but its putative role 
has never been analyzed. In the present study, we described the pattern of expression of 
the GNIP/TRIM7 isoforms, determined the subcellular location of TRIM7 and GNIP1, 








































































2. MATERIALS AND METHODS  
 
2.1. Gene expression analyses   
Total RNA from cultured cells was extracted with the RNeasy Minikit (Qiagen) and 
total RNA from gastrocnemius mouse muscle was extracted with TRIsure reagent 
(Bioline), following the manufacturer's instructions. Human SKM total RNA was from 
Applied Biosystems (FirstChoice Human Skeletal Muscle Total RNA #AM7982). Total 
RNAs were used to perform an RT-PCR using specific primers for human: TRIM7 
(TRIM7 isoform 4), GNIP1 (TRIM7 isoform 1), GNIP2 (TRIM7 isoform 3), GNIP3 
(TRIM7 isoform 2) or mouse:  interleukin-6 (IL-6) and tumor necrosis factor alpha 
(TNF-α). Human β-2 microglobulin or mouse adenine phosphoribosyltransferase 
(APRT) were used as a reference gene. Primer sequences used for RT-PCR are 
displayed in the Supplementary Methods (SM) S1.1.1. 
 
2.2. GST-GNIP1, GST-TRIM7 and GST-GNIP2 recombinant proteins and the in 
vitro autoubiquitination assay 
GNIP1 and TRIM7 cDNAs were cloned into the pGEX4T1 vector (Amersham) 
(cloning site: XhoI for GNIP1 and EcoRI-SalI for TRIM7), and GNIP2 was cloned into 
the pGEX4T2 vector (Amersham) (cloning sites: XhoI-NotI), to produce the GST 
recombinant proteins. 
The pGEX-GNIP/TRIM7 constructions were transformed in BL21 codon plus (DE3) 
RP Escherichia coli. Protein expression was induced and in vitro ubiquitination 
reactions were carried out as described in [12]. 
The samples were subjected to immunoblotting and membranes were hybridized with 








































































2.3. Cytolocation of the fusion construct pGNIP1-EGFP and pTRIM7-EGFP 
Human GNIP1 and TRIM7 cDNA were cloned into the pEGFP-C3 (cloning site: XhoI) 
or pEGFP-C2 (cloning sites: ECoRI-SalI) vectors (Clontech) respectively to obtain 
pGNIP1-EGFP and pTRIM7-EGFP constructs. Colocalization analysis of GNIP1-GFP 
and TRIM7-GFP fusion proteins with Golgi apparatus in LHCN-M2 myoblasts was 
performed as described in [13]. For further details, please refer to the SM S1.1.3. 
 
2.4. Human tissues 
Myoblast cell populations were isolated from a cryopreserved collection of human SKM 
biopsies from Hospital Sant Joan de Déu (Barcelona, Spain). Immunoblot analysis was 
performed using post-mortem muscle tissues from one subject. Immediately after 
excision, all tissue samples were frozen in liquid N2. When stated, tissue samples were 
powdered in a mortar under liquid N2 and thereafter homogenized in the appropriate 
buffer. For further details, please refer to the SM S1.1.4. 
 
2.5. Ethics statement 
The animal protocols were approved by the Universitat de Barcelona Animal Care and 
Use Committee (permit number: DMAH-5444). Animal sacrifice was performed under 
CO2 anesthesia. The human tissue extraction protocol was approved by the ethics 
committee of University Hospital Joan XXIII (Tarragona, Spain) and Hospital Sant 
Joan de Déu (Barcelona, Spain) according to Spanish legislation at that time. The Ethics 
Committee of Hospital Sant Joan de Déu approved the waiver of consent for research. 
For deceased patients, relatives have given signed informed consent.  
 
2.6. Glucose and insulin tolerance test 
The glucose (GTT) or insulin (ITT) tolerance tests were performed on 15- or 12-week-
old conscious mice respectively after 4 hours of fasting. The mice were injected 
intraperitoneally with a glucose bolus (2 g/kg of body weight) or an insulin bolus (1 






































































120 min after glucose administration, as well as at 15, 30, 60 and 90 min after insulin 
administration. Animals were re-fed ad libitum after the test. 
 
2.7. Cultured cells 
Primary cultured myotubes came from a cryopreserved collection of human SKM 
biopsies described in 2.4. Myotubes were derived from confluent myoblast as described 
in [13]. 48 hours before RNA isolation, human myotubes were depleted of insulin and 
24 hours before, they were depleted of FBS. The human SKM cell line LHCN-M2 was 
used as undifferentiated (myoblast) or differentiated (myotubes) for 5 days as described 
in [14]. 24 hours before the experiments, LHCN-M2 cells were incubated with basal 
medium ( DMEM(25mM glucose) /M199 (4:1), 0.02 M Hepes and antibiotics). The 
human AC16 cardiac muscle (CM) cell line was grown as previously described in [15]. 
293 cell line was grown in DMEM (25mM glucose) with 10% (v/v) FBS at 37°C in a 
humid atmosphere of 5% CO2/95% air. 
 
2.8. Transduction with recombinant adenoviruses  
LHCN-M2 myotubes were transduced with recombinant adenoviruses expressing the 
cDNA of human GNIP1 (Ad-GNIP1), TRIM7 (Ad-TRIM7) (ABM Inc.) or GFP (Ad-
GFP) [16] under the control of the CMV cytomegalovirus promoter at a multiplicity of 
infection of 20 for 2 hours, and then incubated for 24 hours.  
For delivery to mice, Ad-GFP or Ad-GNIP1 were purified and injected in two 
gastrocnemius muscles of ICR-CD1 male mice from two separate batches (6 mice for  
Ad-GFP and 6 mice for Ad-GNIP1), as described in [17]. Thereafter, mice were fed 
with standard laboratory chow diet (2014 Tekland Global 14% Protein Rodent 
Maintenance Diet, Harlan Iberica) and water ad libitum. Animals were sacrificed at 16 
weeks of age after an overnight fast. A blood sample was collected and tissues were 








































































2.9.  Enzyme activities,  immunoblotting  and glycogen quantification. 
The measure of GS and GP activities, immunoblotting, and glycogen content of 
gastrocnemius and LHCN-M2 samples was assessed as described in [18] by 
supplementing homogenization buffers with 10 mmol/l iodoacetamide to inactivate 
deubiquitylases and 20 μmol/l proteasome inhibitor MG132 (Sigma-Aldrich), except for 
glycogen measurement.  
293 cell monolayers or human tissue extracts were subjected to immunoblot analysis as 
described in [13]. For human tissues, the homogenization buffer was supplemented with 
40% (v/v) glycerol and 100 mmols/l dithiothreitol. Comercial antibodies used for 
membranes hibridation are displayed in the SM S1.1.6.  
 
2.10. Glucose uptake 
2-Deoxy-d-[1-3H] glucose uptake was assessed in LHCN-M2 myotubes. After 
adenovirus transduction, cells were incubated with basal medium without glucose for 3 
hours. Then, glucose uptake was assayed as described in [19]. 
 
2.11. Statistical analysis  
All data are given as means ± SEM, and the significance of the difference was analyzed 





3.1. Expression pattern of GNIP/TRIM7 isoforms in human muscle tissues and  
cultured cells 
The relative abundance of GNIP/TRIM7 transcripts was assessed in samples of human 






































































1A). In all tested SKM cultured cells, the GNIP1 mRNA level was always much higher 
than TRIM7. In contrast, in the cardiomyocyte AC16 cell line, GNIP1 mRNA was 
undetectable, whereas mRNA levels of TRIM7 were comparable to the ones measured 
in SKM. The mRNA levels of GNIP2 and GNIP3 were undetectable in all measured 
samples (data not shown).  
The GNIP/TRIM7 protein isoforms profile was analyzed in human muscle tissues by 
immunoblot, using an antibody generated against a peptide sequence that is present in 
all GNIP/TRIM7 isoforms. As shown in Figure 1B, the strongest signal corresponding 
to a protein band of the same size as GNIP1 overexpressed in LHCN-M2 cells (Figure 
1C) was observed for SKM tissue. In contrast, the intensity of a protein band of the 
predicted molecular size for TRIM7 (23.7 kDa) and the same size of TRIM7 
overexpressed in LHCN-M2 cells (Figure 1D) was higher in CM. However, these bands 
were not observed in smooth muscle tissue (Figure 1B).  
Therefore, these data suggest that, among the different GNIP/TRIM7 variants, GNIP1 
(isoform 1) is the most abundant form in human SKM, whereas TRIM7 (isoform 4) is 
predominant in CM, both at the mRNA and protein levels.  
 
3.2. Autoubiquitination activity of GNIP/TRIM7 proteins 
Enzymatic activity of E3 ubiquitin ligases can be assayed through autoubiquitination of 
the protein in vitro in the absence of identified substrate. First, in order to find the 
optimum E2 enzyme for GNIP1/TRIM7 proteins, we performed the in vitro 
autoubiquitination assay on GST-TRIM7 using different E2 enzymes. As shown in 
Figure 2A, high molecular weight TRIM7 species indicative of autoubiquitination were 
primarily formed in the presence of UbcH5a and UbcH6 enzymes. Removal of the E2 
enzyme abolished the reaction, which indicates that these high molecular weight 
TRIM7 forms were the products of a polyubiquitination reaction, catalyzed by TRIM7 
E3 and UbcH5a or UbcH6 E2 enzymes. 
Then, we tested the activity of GST fusion proteins of GNIP1 and GNIP2 (as a putative 
negative control), as well as TRIM7, for autoubiquitination with UbcH5a. We found 
that high molecular weight TRIM7 and GNIP1 species were formed in the presence of 






































































(Figure 2B). Membranes were stained with GNIP/TRIM7 antibody and an ubiquitin 
antibody. Both antibodies detect the same protein bands indicating that the specific 
bands are ubiquitinated species of GNIP1 or TRIM7 (Figure 2A and 2B). Together, 
these data  indicate that TRIM7 and GNIP1 have autoubiquitination activity in vitro, 
whereas GNIP2 lacks this activity. 
 
3.3. GNIP1 and TRIM7 intracellular location 
We constructed a fusion protein of GNIP1 or TRIM7 with a C-terminal EGFP flag 
(GNIP1-EGFP or TRIM7-EGFP). Western blotting confirmed the correct expression 
and size of the fusion proteins (Figure 3A, B). 
We analyzed the subcellular location of GNIP1 and TRIM7 proteins in LHCN-M2 
myoblasts. TRIM7-EGFP protein appeared throughout the cytosol with a diffuse 
pattern, and was occasionally located in the nucleus (Figure 3C). In contrast, the 
GNIP1-EGFP protein showed a pattern clustered around the nucleus that was collocated 
with the Golgi marker. As a control, we transfected LHCN-M2 cells with a plasmid 
encoding EGFP, and we observed that this protein was located in the cytoplasm and 
nucleus and was not collocated with Golgi-targeted RFP. 
 
3.4. Effect of GNIP1 overexpression on glycogen metabolism in mouse SKM 
To analyze the possible impact of GNIP1 protein on glycogen metabolism, 
gastrocnemius mouse muscle was treated with the Ad-GNIP1 adenovirus to overexpress 
human GNIP1 or Ad-GFP adenovirus, as a transduction control. In an immunoblot 
analysis, the antibody against GNIP/TRIM7 proteins detected a band in Ad-GFP-treated 
muscle between 60-75 kDa (Figure 4A), which was much more intense in mouse 
muscle treated with Ad-GNIP1 (1320±265 expressed as a percentage of the value 
obtained in gastrocnemius muscle of GFP-mice. p≤ 0.001 (n=12)). Importantly, human 
GNIP1 and GFP protein levels were undetectable in the liver of GNIP1- or GFP-mice 
respectively (data not shown). Therefore, we concluded that no systemic distribution of 






































































 We analyzed changes in body weight and blood glucose levels at various time points 
after adenovirus transduction. To analyze whole-body insulin sensitivity in relation to 
GNIP1 overexpression, we also performed an ITT and a GTT. The body weight of 
GNIP-1 mice was statistically reduced by about 8% after day 85 post-adenoviral 
infection (Figure 4B). In the same way, from day 44, the blood glucose levels were 
about 15% lower in GNIP1-mice than in GFP-mice (Figure 4C). In contrast, whole-
body insulin and glucose tolerance were unaffected by GNIP1 gene delivery (Figures 
4D, E). After overnight fasting, blood glucose levels remained lower in GNIP1-mice 
than in GFP-mice, although this difference did not reach statistical significance (Table 
1A). Lactate levels were clearly decreased by GNIP1, whereas insulin levels were 
unaffected. Body weight was lower in GNIP1-mice than in GFP-mice (Table 1B) but 
we did not observe differences between groups in body weight/liver or adipose tissue 
ratios.  
We next studied the effect of GNIP1 overexpression on GS and GP activities and its 
impact on glycogen accumulation and GYG1 protein content in gastrocnemius muscle. 
The activity of the total and active form of GS in GNIP1-mice gastrocnemius muscle 
increased about 34% (Figure 5A), and 22% (Figure 5B) respectively compared to 
control muscles, whereas GS activity ratio (-G6P/+G6P) was unafected by GNIP1 
(GFP-mice = 0.14 ± 0.02; GNIP1-mice = 0.12 ± 0.01; p = 0.2). No effects of GNIP1 
overexpression were observed on GP activity (Figure 5C, D). In concordance with the 
GS activation, the glycogen levels in gastrocnemius muscle were 40% higher in GNIP1-
mice than in GFP-mice (Figure 5E), whereas no significant changes were observed in 
GYG1 protein content (Figure 5F).  
To decipher the molecular mechanism underlying GS activation, we investigated 
possible GNIP1-mediated regulation of the protein kinase B (Akt)-glycogen synthase 
kinase-3 (GSK-3)-GS signaling cascade. No changes were observed in total Akt, GSK-3 
or GS protein content in relation to GNIP1 overexpression (Figure 6), but a significant 
increase in phospho-Akt/total Akt (47%) and phospho-GSK-3/total GSK-3 (53%) 
protein content ratios was observed. Accordingly, phosphorylation of GS in Ser 
640/total GS ratio was about 30%  lower in GNIP1 overexpressed muscle.   
To determine whether GNIP1 can regulate pro-inflammatory mediators, the mRNA 






































































measured by real-time PCR. No changes in TNF-α (2-∆∆Ct =1.05 ± 0.16, p=0.89 (n=9) ) 
or IL-6 (2-∆∆Ct = 1.08 ± 0.13, p=0.84 (n=9) ) gene expression were observed in GNIP1-
mice compared to GFP-mice.  
Thus, together these data suggest that GNIP1 overexpression in mouse muscle in vivo 
leads to decreased blood glucose levels, lactate levels and body weight, and  activates 
the Akt-GSK-3-GS signaling pathway and glycogen accumulation without altering the 
inflammatory status of gastrocnemius muscle. 
 
3.5. Effect of GNIP1 on glucose transport and GS activity in LHCN-M2 myotubes 
We analyzed whether these effects were accompanied by an increase in glucose 
transport through the cell membrane. To achieve this, we performed an adenoviral gene 
transfer of GNIP1, TRIM7 and GFP in cultured LHCN-M2 myotubes and determined 2-
deoxyglucose uptake in the presence or absence of insulin. 
Human GNIP1 and TRIM7 overexpression was confirmed by immunoblot, showing 
bands in Ad-GNIP1- and Ad-TRIM7-treated cells of about 60-75 kDa and 20-25 kDa 
respectively (Figure 7A), which were not found in cells treated with Ad-GFP 
adenovirus.  
Next, we confirmed that basal glucose uptake was increased in response to GNIP1 
(30%) and TRIM7 (20%) overexpression (Figure 7B). As expected, insulin increased 2-
deoxyglucose uptake by 25% in myotubes treated with Ad-GFP. In the presence of 
insulin, GNIP1 overexpression further stimulated 2-deoxyglucose uptake (27%), 
whereas no effect of TRIM7 was observed under this condition. This indicates that 
TRIM7 increases glucose transport through the cell membrane, less than GNIP1 and in 
the absence of insulin only. However,  GNIP1 can enhance glucose uptake additively to 
insulin. 
To analyze whether Akt-GSK-3-GS pathway activation observed in GNIP1-mice 
gastrocnemius muscle is dependent on the phosphoinositide 3-kinase (PI3K), GS ativity 
was measured  in the presence and absence of insulin or/and LY294 (an inhibitor of 
PI3K) in LHCN-M2 cultured  myotubes. Insulin increased GS activity ratio (-






































































activation of GS by insulin was blocked by LY294. GNIP1 overexpression caused a 
significant GS activation  that did not reach statistical significance in LY294 treated 
cells.  These data suggest that GS activation by GNIP1 is partially dependent on PI3K. 
  
4. DISCUSSION 
It is well known the importance of the interaction between GYG1 and GS for glycogen 
biosynthesis in muscle, and GNIPs have recently emerged as a proteins with a novel 
putative role in glycogen metabolism. 
GNIP1 and GNIP2 are known to interact with GYG1 and GNIP2 to stimulate GYG1 
self-glucosylation in vitro [2]. The B30.2 domain, which is present in GNIP1 and 
GNIP2, mediates interaction with GYG1 [5]. Autoglucosylation of GYG1 leads to the 
formation of a maltosaccharide chain that acts as the primer for GS and branching 
enzyme to accomplish glycogen synthesis [20]. We demonstrated here that GNIP1 
overexpression in mouse SKM increased the glycogen accumulation and did not change 
GYG1 protein content. Thus, our data, together with previous studies, point to a likely 
interaction between GNIP1 and GYG1 that improve GYG1 self-glucosylation in vivo, 
which promotes glycogen synthesis without altering GYG1 protein content. Skurat et al. 
proposed that the stimulatory effect of GNIP2 on GYG1 self-glucosylation in vitro 
occurs via a change in the conformation of the GYG1 dimer that creates a better 
condition for attachment of glucose to the polysaccharide chain [2]. Thus, GNIP1 could 
exert this same action on GYG1 in vivo.  
On the other hand, our results confirm that GNIP1 has E3 ubiquitin ligase activity that 
GNIP2 does not have. GNIP1 and TRIM7-deduced proteins have been found to contain 
an N-terminal RING domain [3], which suggests they could have E3 ubiquitin ligase 
activity. Recently, Chakraborty et al. characterized human GNIP1 as an ubiquitin ligase 
with a role in activator protein 1 (AP-1) activation via Ras,  through an in vivo 
ubiquitination assay in 293T cells [11]. Here, for the first time, we demonstrate 
enzymatic activity as an E3 ubiquitin ligase for TRIM7, and confirm this activity for 
GNIP1 through in vitro autoubiquitination. Initially, ubiquitination was defined as a tag 






































































for ubiquitination, such as regulation of binding properties, subcellular localization and 
activity [9, 10, 21].   
It is known that the coiled-coil domain of TRIM family proteins promotes the definition 
of discrete subcellular compartments within the cell [22]. Previous data suggest possible 
involvement of the TRIM proteins and their alternatively spliced isoforms in the 
regulation of compartmentalization [3]. Moreover, regulation by ubiquitination can 
occur via the subcellular localization of the enzymes, the substrates or via binding to 
“auxiliary” proteins [23]. In this regard, we show that TRIM7 is mostly present in the 
cytosol and occasionally in the nucleus of cultured human SKM cells. This is in 
agreement with previous data, which determined TRIM7 localization in a diffuse 
cytoplasmatic and nuclear pattern in HeLa and U2OS cells [3]. Otherwise, the cellular 
localization of GNIP1, which has never before been described, was in the Golgi 
apparatus. Thus, we speculate that the different structure domain of GNIP1 and TRIM7 
is presumably responsable for their different intracellular localization, and probably for 
their different function in SKM.  
The human tissue expression profile of the GNIP/TRIM7 gene using a partial coding 
sequence for TRIM7 is reported to be most prominent in SKM [2]. However, the tissue 
distribution of GNIP/TRIM7 proteins in mouse extracts analyzed using antibodies 
generated against the C-terminal B30.2 domain present in GNIP1, GNIP2, GNIP3 (not 
in TRIM7) revealed a 55 kDa species (the same size as GNIP1 expressed in COS cells) 
in several tissues, and relatively low levels in SKM [5]. In the present study, using an 
antibody against a sequence in the N-terminal part of GNIP1, GNIP2 and GNIP3 and 
the C-terminal part of TRIM7, we detected stronger signals for these proteins in human 
SKM and CM samples than in smooth muscle tissue. Specifically, GNIP1 showed the 
strongest signal in SKM, whereas for TRIM7 the highest content was observed in CM. 
In agreement with these results, GNIP1 mRNA levels were higher than TRIM7 in 
human SKM cultured cells, whereas in human cardiomyocytes only TRIM7 was 
expressed. 
The main glycogen stores are confined to SKM and liver in humans,  although SKM is 
the major tissue where insulin stimulates glucose uptake to store glycogen and remove 
glucose from the blood [24]. Insulin regulates glucose metabolism by the 






































































activation and a subsequent phosphorylation cascade that activates and phosphorylates 
Akt. The activated phospho-Akt then inactivates GSK-3 by phosphorylation, which is 
involved in GS regulation by phosphorylation at site 3a [25, 26]. We observed an 
increment in GS activation by dephosphorylation in ser 640, accompanied by an 
activating effect on the insulin Akt-GSK-3 signaling cascade in GNIP1-mice, and an 
increment in glucose uptake in GNIP1-overexpresed cultured LHCN-M2 myotubes. It is 
known that some ubiquitination processes are involved in the regulation of glycogen 
accumulation. For instance, the RING-type E3 ubiquitin ligase malin ubiquitinates GS 
and GP in cultured cells, and regulates expression and phosphorylation levels of GP in 
mouse [27]. However, it has never been demonstrated that malin directly regulates 
glycogen metabolism by controlling the GS activation state or phospho-GS or total GS 
protein content levels in mouse muscle in vivo [28]. Our results showed that GNIP1, on 
the contrary, did not elicit any effect on GP activity, but increased GS activation as well 
as Akt and GSK-3 phosphorylation levels in mouse. Furthermore, our findings in 
LHCN-M2 cultured cells suggest that GNIP1-mediated activation of GS is partially 
dependent on PI3K.  This upregulation of the insulin signaling pathway by GNIP1 
might be occurring through an ubiquitination process of a protein directly or indirectly 
involved in this pathway. Other ubiquitin ligases located in Golgi apparatus can regulate 
metabolic signaling pathways by ubiquitin-mediated modification of molecules 
involved in up- or down-regulation of these pathways [29, 30]. Currently, RACO-1 is 
the only substrate described for GNIP1, which stimulates c-Jun/AP-1 activation [11]. c-
Jun N-terminal kinases have been considered signaling molecules, linking inflammation 
and insulin resistance [31], and have been identified as a substrate of GSK-3 [32, 33]. It 
has been described that some E3 ubiquitin ligases regulate insulin signaling through 
targeting pro-inflammatory mediators involved in insulin resistance (review [34]). In 
this regard, although more pro-inflammatory markers should be assessed to confirm our 
results, they might suggest that pro-inflammatory mediators expression is not modulated 
by GNIP1 in mouse muscle.   
Recently, TRIM family proteins were found to be implicated in the regulation of insulin 
pathway. An example is the muscle-specific MG53 (also called TRIM72) that mediates 
the degradation of IRS1 and, when upregulated in mouse, causes metabolic syndrome 
featuring insulin resistance, obesity, hypertension and dyslipidemia [6]. Our results 






































































decreased mouse body weight and blood circulating glucose and lactate levels. We 
propose that this effect is due,  in part,  to GNIP1-mediated activation of the Akt-GSK-
3-GS signaling cascade and subsequent glycogen synthesis in muscle. In a recent study, 
muscle-specific GS deletion in adult mice showed increased lactate levels, decreased 
muscle glycogen content and glucose intolerance [35]. However, in other studies, 
modification of GS activity and muscle glycogen stores in muscle resulted in 
normoglycemic animals [36, 37]. Our findings showed no effects of GNIP1 on glucose 
tolerence in mouse. Therefore, other mechanisms migt mediate the reduced blood 
glucose and lactat levels in Ad-GNIP1 treated-mice. Previous studies in human have 
found that muscles break down glycogen to lactate during intense exercise, and during 
the recovery period, muscle glycogen reappears while lactate disappears [38]. Our 
results showed that GNIP1 is  mainly expressed in SKM in humans and  Zhai et al. [5]  
have proposed that GNIP1 might be a factor responsable for controlling the rate of 
reassociation of GYG1 and GS during glycogen-resynthesis in muscle. Therefore, we 
speculate that GNIP1 overexpression in gastrocnemius mouse muscle could be 
mimicking certain processes associated  to the recovery period after exercise. 
 In human muscle cultured cells GNIP1 increased glucose uptake additibely to insulin. 
However, a lack of effect of GNIP1 on whole-body insulin tolerance was observed in 
mice. The reason for this discrepancy may be that some processes associated to the in 
vivo model could not be happenning in cultured cells. We find several similarities 
between our findings and the results obtained by Ruisheng S. et al. [6]. In their study, 
MG53 deficiency markedly attenuated high-fat diet-induced metabolic syndrome. 
However, no effects were observed in animals fed with a standard chow diet, excepte 
for a reduction in blood glucose concentration. So, we should also consider that dietary 
intervention could be important to detect the potential effects of GNIP1 on insulin or 
glucose  response in mouse. 
We observed a GNIP1-mediated increase of GS activity ratio (-G6P/+G6P) in human 
LHCN-M2 cells that was not detected in mouse. However, the activity of the total 
(+G6P) and active (-G6P) form of GS was increased in GNIP1-mice, without altering 
GS protein content. An unusual disconnection between total GS activity and GS protein 
content has been already observed by other authors [39, 40]. The reason for this effect is 
unclear but it may reflect a mechanism of GNIP1 to modify the total enzyme activity.  It 
is also possible that other mechanisms may make GS more sensitive to G6P in GNIP1-






































































The activation of the insulin signaling pathway by GNIP1 is in accordance with the 
observed increment in glucose uptake in cultured cells. It is known that Akt plays a role 
in directing GLUT4 vesicles to the plasma membrane and thus promotes glucose 
transport in 3T3-L1 adipocytes [41]. Constitutive activation of Akt in L6 muscle cells, 
also stimulates the uptake of glucose and promotes the inactivation of GSK-3 and 
glycogen sinthesis [42] . Therefore, our data suggest that GNIP1 can enhance glucose 
transport and , at least in part, GS activity by increasing phospho-Akt levels. However,  
since GNIP1 was capable of stimulating glucose uptake in LHCN-M2 cells, both in the 
presence and absence of insulin,  we cannot discard a possible non-insulin dependent 
action of GNIP1 on basal glucose uptake, more dependent of GLUT1 in SKM [43].  
Together, our results suggest that defects in GNIP1 in skeletal muscle could be involved 
in pathogenesis and insulin resistance. However, further studies are needed to determine 
whether GNIP1  could be considered a treatment option for diabetes and obesity. 
In summary, the present study demonstrates that GNIP1 can stimulate glycogen 
synthesis and promote the insulin signaling pathway activation and glucose uptake in 
SKM. This indicates that GNIP1 is an E3 ubiquitin ligase enzyme with a new, emerging 
role in glycogen metabolism, that could be a potential therapeutic target for the 
treatment of obesity or type 2 diabetes.    
 
FIGURE LEGENDS  
FIGURE 1. GNIP/TRIM7 expression in human tissues. (A) The relative expression 
of TRIM7 and GNIP1 genes was analyzed in human SKM, primary cultured myotubes 
(PCMT), LHCN-M2 (MB= myoblast, MT=myotube) and AC16 cells by RT-PCR. 
Percentage of mean values of 2-∆Ct ± SEM are shown. The significance of differences 
versus SKM: *p < 0.05; ** p < 0.01 and versus GNIP1 in the same tissue or cell type:† 
p < 0.05; ‡ p < 0.01. (B) Immunoblot analysis was performed on extracts from the 
indicated human mucle tissues or (C) from human skeletal muscle and cultured LHCN-
M2 myoblasts treated with Ad-GFP or Ad-GNIP1 or (D) from human cardiac muscle 
and cultured LHCN-M2 myoblasts treated with Ad-TRIM7. Membranes were 
hybridized with antibodies against GNIP/TRIM7 (B, C, D) and α-actinin (C, D). GNIP1 






































































FIGURE 2. Autoubiquitination assay on TRIM7, GNIP1 and GNIP2. (A) GST-
TRIM7 or (B) GST-GNIP1, GST-GNIP2 and GST-TRIM7 were incubated in the 
ubiquitination reaction mix, without (-) or with the indicated human E2 enzymes.  
Immunoblot was performed and membranes were hybridized with indicated antibodies. 
A representative image is shown. 
FIGURE 3. Cytolocation of GFP-GNIP1 and GFP-TRIM7. 293 cells were 
transfected with pEGFP, pEGFP-GNIP1 or pEGFP-TRIM7 and immunoblot analysis 
was performed using (A) anti-GNIP/TRIM7 or (B) anti-GFP antibodies. (C) LHCN-M2 
myoblasts were co-transfected with pRFP1-N1-GalT (Golgi marker) and (a to d) 
pEGFP (e to h) pEGFP-TRIM7 or (i to l) pEGFP-GNIP1. The image shows the 
fluorescent signal of Hoechst (a, e, i), EGFP (b, f, j), RFP (c, g, k) and the colocation of 
the signal of Hoechst, EGFP and RFP (d, h, l). 
FIGURE 4. Effect of GNIP1 on mouse. (A) Immunoblot analysis was performed on 
gastrocnemius extracts from GFP- and GNIP1-mice using antibodies against 
GNIP/TRIM7 and actin. Body weight (B) and blood glucose levels (C) were measured 
on the days indicated. An (D) ITT or (E) GTT was performed. Data are mean ± SEM 
(n=6). Significance of differences versus GFP-mice: *p < 0.05; ** p < 0.01. 
TABLE 1. Body and tissue weight, blood metabolites and insulin levels in GFP- 
and GNIP1-mice. (A) Blood glucose, lactate and insulin levels and (B) body (Bw), 
liver (Lw) and peritoneal white adipose tissue (Aw) weight were measured in overnight 
fasted mice at 113 days of age. Data are mean ± SEM (n=6). Significance of differences 
versus GFP-mice: *p < 0.05. 
FIGURE 5. Effects of GNIP1 on overexpressed mouse muscle. Gastrocnemius 
muscle extracts from GFP- and GNIP1-mice were used to perform total (A) GS or (C) 
GP activity and active (B) GS or (D) GP activity measures, (E) glycogen content and 
(F) immunoblot analysis with anti- GYG1 and anti-actin antibodies. Data are means ± 
SEM (n=12). Significance of differences versus GFP-mice muscle: *p < 0.05; **p < 
0.01. 
FIGURE 6. GNIP1 effects on the Akt-GSK-3-GS signaling cascade. Immunoblot 
analysis was performed on gastrocnemius muscle extracts from GFP- and GNIP1-mice 






































































phospho-GSK-3α/β (Ser21/9) and phospho-Akt (Ser473). Data are mean ± SEM of 
phospho-protein /total protein percentage of GNIP1-mice versus GFP-mice band 
intensity ratio (n=12). Significance of differences versus GFP-mice muscle: *p < 0.05; 
**p < 0.01. 
FIGURE 7. Effect of GNIP1 and TRIM7 on glucose uptake. Overexpressed cultured 
LHCN-M2 myotubes were used to (A) perform an immunoblot analysis using 
antibodies against GNIP/TRIM7 and GAPDH or α-actinin or (B) a glucose uptake 
measure in the presence or absence of insulin. Data are mean ± SEM (n=8). 
Significance of differences versus cells treated with Ad-GFP under the same incubation 
conditions: *p < 0.05; **p < 0.01; or without insulin under the same transduction 
conditions: † p < 0.05. 
FIGURE 8. Effect of GNIP1, insulin and LY294 on GS activity in LHCN-M2 cells. 
LHCN-M2 myotubes were transduced with Ad-GFP or Ad-GNIP1 and incubated with 
25 mM glucose for 24h. Then, cells were incubated with glucose-deprived medium for 
3 h. Finally cells were incubated with 10 mM glucose and with DMSO(control) or 
10μM LY294 inhibitor (Sigma-Aldrich) and/or 100 nM insulin during 30 min. GS 
activity ratio (without glucose 6-phosphate / with glucose 6-phosphate) was measured in 
cell extracts. Data are means ± SEM (n=5). Significance of differences versus cells 
treated with Ad-GFP (DMSO): *p < 0.01; **p < 0.001;  or versus cells treated with 
insulin under the same transduction conditions: †p < 0.05; ‡p≤0,01 
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